Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Stocks in this Quantisnow insightHealth Care
Ask Ellis, your AI research assistant, about this story
Keep researching ARVN
Quantisnow market dataNASDAQ
ARVN
Arvinas Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for ARVN
Full ARVN profile on Quantisnow Follow ARVN and get a push notification the moment its next story breaks.